The ALGONQUIN Study: A Phase 1/2 Multi-Center, Dose Escalation Study to Determine the RP2D, Safety and Efficacy of GSK2857916 in Combination with Pomalidomide and Low Dose Dexamethasone in Subjects with RRMM